Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Meisel

Showing results (171-180 of 310) with videos related to

Pageof 31
Sort By:
Molecular Neurodegeneration|April 19, 2015
Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathwayKaren Rosenberger, Paul Dembny, Katja Derkow, et al.
European Journal of Neurology|January 31, 2022
Daratumumab for treatment-refractory antibody-mediated diseases in neurologyFranziska Scheibe, Lennard Ostendorf, Harald Prüss, et al.
European Journal of Neurology|November 14, 2025
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and ControlsAmol K Bhandage, Sarah Hoffmann, Carla Dusemund, et al.
Journal of Neurology|October 21, 2019
Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitisFranziska Scheibe, Lennard Ostendorf, S Momsen Reincke, et al.
European Journal of Neurology|October 7, 2024
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravisAli A Habib, Michael Benatar, Tuan Vu, et al.
Neurology and Therapy|June 23, 2023
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Annals of the New York Academy of Sciences|June 24, 2008
Thoracoscopic thymectomy with the da Vinci robotic system for myasthenia gravisJens C Rückert, Mahmoud Ismail, Marc Swierzy, et al.
Plos One|April 22, 2014
Histone acetylation and CREB binding protein are required for neuronal resistance against ischemic injuryFerah Yildirim, Shengbo Ji, Golo Kronenberg, et al.
The Annals of Thoracic Surgery|March 20, 2019
Results of Robotic Thymectomy Performed in Myasthenia Gravis Patients Older Than 60 Years at OnsetFeng Li, Reona Takahashi, Gero Bauer, et al.
Muscle & Nerve|May 5, 2023
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scoresSarah Dewilde, M F Janssen, Nafthali H Tollenaar, et al.
Pageof 31

Showing results (171-180 of 310) with videos related to

Sort By:
Pageof 31
Molecular Neurodegeneration|April 19, 2015
Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathwayKaren Rosenberger, Paul Dembny, Katja Derkow, et al.
European Journal of Neurology|January 31, 2022
Daratumumab for treatment-refractory antibody-mediated diseases in neurologyFranziska Scheibe, Lennard Ostendorf, Harald Prüss, et al.
European Journal of Neurology|November 14, 2025
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and ControlsAmol K Bhandage, Sarah Hoffmann, Carla Dusemund, et al.
Journal of Neurology|October 21, 2019
Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitisFranziska Scheibe, Lennard Ostendorf, S Momsen Reincke, et al.
European Journal of Neurology|October 7, 2024
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravisAli A Habib, Michael Benatar, Tuan Vu, et al.
Neurology and Therapy|June 23, 2023
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisTuan Vu, Andreas Meisel, Renato Mantegazza, et al.
Annals of the New York Academy of Sciences|June 24, 2008
Thoracoscopic thymectomy with the da Vinci robotic system for myasthenia gravisJens C Rückert, Mahmoud Ismail, Marc Swierzy, et al.
Plos One|April 22, 2014
Histone acetylation and CREB binding protein are required for neuronal resistance against ischemic injuryFerah Yildirim, Shengbo Ji, Golo Kronenberg, et al.
The Annals of Thoracic Surgery|March 20, 2019
Results of Robotic Thymectomy Performed in Myasthenia Gravis Patients Older Than 60 Years at OnsetFeng Li, Reona Takahashi, Gero Bauer, et al.
Muscle & Nerve|May 5, 2023
Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scoresSarah Dewilde, M F Janssen, Nafthali H Tollenaar, et al.
Pageof 31